← All trials
NCT01726413
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 1, 2012
- Primary completion
- Aug 1, 2014
- Completion date
- Sep 1, 2014
- First posted
- —
- Last posted
- —
- Enrollment
- 138
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Glenmark PharmaceuticalsLead sponsor
- K.L.E.S Dr. Prabhakar Kore Hospital & Medical research CentreOverall official - principal investigator
- TOTALL Diabetes Hormone InstituteOverall official - principal investigator
- Jnana Sanjeevani Medical CentreOverall official - principal investigator
- Getwell Hospital and Research CentreOverall official - principal investigator
- Bangalore ClinisearchOverall official - principal investigator
- Arthur Asirvathma HospitalOverall official - principal investigator
- DADO Medical s.r.oOverall official - principal investigator
- ICONOverall official - principal investigator
- Jehangir Clinical Development Centre Pvt. Ltd.Overall official - principal investigator
- Kovai Medical Centre and Hospital, CoimbatoreOverall official - principal investigator
- MV Hospital and Research CenterOverall official - principal investigator
- NeuroHelpOverall official - principal investigator
- Azad UniversityOverall official - principal investigator
- Glenmark PharmaceuticalsCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.